Hospital
Prisma Health-Midlands
Prisma Health-Midlands was paid $11.77M by Medicaid between Jan 2018 and Dec 2024, across 143 billing codes. Its largest line is 99283, emergency room visit (moderate) — 12% of everything it billed.
33Billing provider infoPRISMA HEALTH-MIDLANDS
COLUMBIA, SC 29201
COLUMBIA, SC 29201
33aNPI1205889458assigned 05/18/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$11.77M
24GClaims219,359
24DCodes billed143
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in South Carolina
Rank by total paid#29 of 115
Median peer was paid$2.47M
This provider vs. median4.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official MILLER, POLLY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 26,041 | $1.15M | |
| 2019 | 31,748 | $1.44M | |
| 2020 | 28,686 | $1.28M | |
| 2021 | 33,321 | $2.01M | |
| 2022 | 37,909 | $2.48M | |
| 2023 | 35,631 | $2.22M | |
| 2024incomplete | 26,023 | $1.19M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 12% | 14,317 | 12,675 | $1.45M |
| 81025 | 12% | 8,212 | 7,851 | $1.40M | |
| 80048 | Basic metabolic panel (calcium, ionized) | 9.0% | 6,448 | 5,770 | $1.06M |
| 80053 | Comprehensive metabolic panel | 7.5% | 7,747 | 6,779 | $886K |
| 36415 | Collection of venous blood by venipuncture | 5.3% | 4,653 | 3,282 | $622K |
| 94010 | 4.8% | 873 | 871 | $568K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 4.7% | 4,861 | 3,482 | $553K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 4.2% | 2,919 | 2,891 | $492K |
| 81001 | 3.6% | 10,774 | 9,961 | $419K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.4% | 2,491 | 2,225 | $397K |
| 96361 | Intravenous infusion, hydration; each additional hour | 3.4% | 4,943 | 4,095 | $397K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 3.2% | 11,161 | 10,277 | $373K |
131 more codes
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.3% | 5,127 | $274K |
| 84702 | 2.0% | 2,269 | $236K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.7% | 1,607 | $202K |
| 85027 | 1.6% | 3,352 | $186K | |
| 99285 | Emergency room visit (most serious) | 1.4% | 4,964 | $162K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.2% | 12,401 | $144K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.0% | 1,355 | $119K |
| 86900 | <1% | 1,269 | $108K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,305 | $101K |
| 87210 | <1% | 904 | $92K | |
| 76830 | Ultrasound, transvaginal | <1% | 510 | $83K |
| 86850 | <1% | 749 | $80K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 633 | $73K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 1,543 | $71K |
| 84112 | <1% | 201 | $61K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,583 | $61K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,986 | $61K |
| 76642 | <1% | 878 | $58K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 862 | $56K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,138 | $52K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 1,193 | $49K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 8,114 | $46K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,951 | $43K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,517 | $42K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 993 | $42K |
| G0378 | Hospital observation service, per hour | <1% | 2,204 | $41K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 24 | $41K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 438 | $40K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 960 | $40K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 5,110 | $38K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 222 | $34K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 5,715 | $33K |
| J3490 | Unclassified drugs | <1% | 3,284 | $31K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 182 | $29K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,678 | $22K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 120 | $21K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 944 | $20K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 159 | $20K |
| 87077 | <1% | 324 | $17K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 6,342 | $15K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 168 | $13K |
| 94761 | <1% | 267 | $13K | |
| 81003 | <1% | 296 | $12K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 4,261 | $11K |
| 76801 | <1% | 379 | $10K | |
| 96376 | <1% | 1,475 | $10K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 142 | $9K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,252 | $8K |
| 86901 | <1% | 1,287 | $8K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 62 | $8K |
| 83735 | <1% | 3,711 | $7K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 14 | $7K |
| 88307 | <1% | 147 | $7K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 510 | $5K |
| 82731 | <1% | 15 | $5K | |
| 87081 | <1% | 52 | $4K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,214 | $4K |
| 84484 | <1% | 2,661 | $4K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 49 | $4K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 104 | $4K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 542 | $4K |
| 88304 | <1% | 52 | $4K | |
| 77066 | Tomosynthesis, mammo | <1% | 27 | $4K |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 98 | $4K |
| 82570 | <1% | 531 | $3K | |
| J2704 | Injection, propofol, 10 mg | <1% | 607 | $3K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 107 | $3K |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 962 | $3K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 475 | $2K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 49 | $2K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,368 | $2K |
| 88342 | <1% | 133 | $2K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,582 | $2K |
| 84703 | <1% | 154 | $2K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,914 | $2K |
| 73560 | <1% | 17 | $2K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,737 | $1K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,202 | $1K |
| 93976 | <1% | 760 | $1K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 251 | $1K |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 217 | $791.86 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 313 | $791.32 |
| 82550 | <1% | 109 | $770.52 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 50 | $769.36 |
| 76937 | <1% | 16 | $758.36 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 68 | $752.71 |
| 83690 | <1% | 3,148 | $710.42 | |
| 85610 | <1% | 473 | $527.42 | |
| 80069 | <1% | 13 | $486.12 | |
| 84156 | <1% | 576 | $459.11 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 305 | $457.70 |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 14 | $368.16 |
| 85379 | <1% | 185 | $256.96 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 904 | $91.12 |
| 86803 | <1% | 26 | $63.30 | |
| 83880 | <1% | 87 | $37.94 | |
| 84100 | <1% | 101 | $26.36 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 303 | $23.25 |
| 83605 | <1% | 143 | $15.40 | |
| 87186 | <1% | 89 | $7.57 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 586 | $6.72 |
| 85730 | <1% | 200 | $6.16 | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 127 | $0.90 |
| 84550 | 0% | 464 | $0.00 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 46 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 815 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 54 | $0.00 |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 235 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 210 | $0.00 |
| 59025 | Fetal non-stress test | 0% | 64 | $0.00 |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | 0% | 39 | $0.00 |
| 80076 | 0% | 18 | $0.00 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 12 | $0.00 |
| 99152 | 0% | 20 | $0.00 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 47 | $0.00 |
| A4311 | Insertion tray without drainage bag with indwelling catheter, foley type, two-way latex with coating (teflon, silicone, silicone elastomer or hydrophilic, etc.) | 0% | 13 | $0.00 |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 0% | 18 | $0.00 |
| J3105 | Injection, terbutaline sulfate, up to 1 mg | 0% | 27 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 16 | $0.00 |
| 83615 | 0% | 361 | $0.00 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 150 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 27 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 37 | $0.00 |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | 0% | 54 | $0.00 |
| 84443 | Thyroid stimulating hormone (TSH) | 0% | 144 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 50 | $0.00 |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 0% | 63 | $0.00 |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 0% | 69 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 14 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 59 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 37 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMILLER, POLLY (SVP FINANCE, ENTERPRISE CONTRACTING)
| Provider | Location | Paid |
|---|---|---|
| Prisma Health-Midlands | Columbia, SC | $74.58M |
| Prisma Health-Midlands | Columbia, SC | $68.26M |
| Prisma Health-Upstate | Greenville, SC | $25.04M |
| Prisma Health-Upstate | Greenville, SC | $21.98M |
| Prisma Health-Upstate | Greenville, SC | $19.69M |
| Prisma Health-Upstate | Seneca, SC | $15.64M |
| Prisma Health-Upstate | Greenville, SC | $10.74M |
| Greenville Health Corporation | Greenville, SC | $8.90M |
| Prisma Health-Upstate | Greenville, SC | $8.32M |
| Prisma Health-Upstate | Greenville, SC | $7.45M |
| Prisma Health University Medical Group | Greenville, SC | $7.44M |
| Prisma Health-Midlands | Coulmbia, SC | $7.43M |
| Prisma Health-Midlands | Columbia, SC | $6.88M |
| Prisma Health Tuomey | Sumter, SC | $6.84M |
| Prisma Health-Midlands | Columbia, SC | $6.77M |
| Prisma Health-Upstate | Greenville, SC | $6.37M |
| Prisma Health-Upstate | Greenville, SC | $5.00M |
| Prisma Health-Upstate | Greenville, SC | $4.65M |
| Prisma Health-Midlands | Columbia, SC | $4.63M |
| Prisma Health-Upstate | Seneca, SC | $4.48M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.